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Abstract
The bleomycins (BLMs), tallysomycins (TLMs), phleomycin, and zorbamycin (ZBM) are 
members of the BLM family of glycopeptide-derived antitumor antibiotics. The BLM-producing 
Streptomyces verticillus ATCC15003 and the TLM-producing Streptoalloteichus hindustanus 
E465-94 ATCC31158 both possess at least two self-resistance elements, an N-acetyltransferase 
and a binding protein. The N-acetyltransferase provides resistance by disrupting the metal-binding 
domain of the antibiotic that is required for activity while the binding protein confers resistance by 
sequestering the metal-bound antibiotic and preventing drug activation via molecular oxygen. We 
recently established that the ZBM producer, Streptomyces flavoviridis ATCC21892, lacks the N-
acetyltransferase resistance gene and that the ZBM-binding protein, ZbmA, is sufficient to confer 
resistance in the producing strain. To investigate the resistance mechanism attributed to ZbmA, we 
determined the crystal structures of apo and Cu(II)-ZBM-bound ZbmA at the high resolutions of 
1.90 Å and 1.65 Å, respectively. Comparison and contrast with other structurally characterized 
members of the BLM-binding protein family revealed key differences in the protein-ligand 
binding environment that fine-tunes the ability of ZbmA to sequester metal-bound ZBM and 
supports drug sequestration as the primary resistance mechanism in the producing organisms of 
the BLM-family of antitumor antibiotics.
The bleomycin (BLM) family of glycopeptide-derived antibiotics are natural products used 
in clinical chemotherapy treatments against lymphomas, testicular cancer, and squamous 
cell carcinomas.1–4 BLMs cause sequence-specific, metal-dependent oxidative cleavage of 
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double-stranded DNA5, 6 and certain tertiary structures of RNA.7 BLMs consist of four 
structural domains: (i) the metal-binding domain containing pyrimidoblamic acid and β-
hydroxyhistidine, (ii) the DNA-binding domain comprised of the bithiazole moiety and C-
terminal amine, in cooperation with the aminopyrimidine ring, (iii) a linker domain joining 
the DNA- and metal-binding domains, and (iv) a disaccharide moiety responsible for cell 
selectivity and impacting DNA cleavage activity.3, 8–12 Five nitrogen atoms within the 
metal-binding domain, with the primary amine of the β-aminoalanine moiety as the axial 
ligand, coordinate iron and oxygen in the active form of the antibiotic (Fig. 1).13
The BLMs, tallysomycins (TLMs), phleomycins (PLMs), and zorbamycin (ZBM) are 
structurally- and functionally-related glycopeptides (Fig. 1).14–17 The metal-binding domain, 
including the five metal-binding nitrogens, is strictly conserved in all family members. The 
three major structural differences within the BLM family of antibiotics are: (i) bithiazole 
moieties in the BLMs and TLMs versus thiazolinyl-thiazole moieties in the PLMs and ZBM, 
(ii) a unique terminal amine of ZBM in comparison to the other family members that share 
many of the same C-terminal amines, and (iii) the same disaccharide moiety consisting of L-
gulose-3-O-carbamoyl-D -mannose in BLMs, TLMs, and PLMs in contrast to the unique 6-
deoxy- L-gulose-containing disaccharide in ZBM; an additional sugar, 4-amino-4,6-
dideoxy- L-talose, is also present in the linker domain of TLM.
Antibiotic producers contain intrinsic elements within their genomes that provide self-
resistance to the lethal compounds they produce. In addition to the four major mechanisms 
of resistance to antibiotics – antibiotic modification or destruction, target modification, 
antibiotic efflux, and metabolic pathway circumvention18 – antibiotic sequestration is 
another possible mechanism.19–21 The bleomycin producer, Streptomyces verticillus 
ATCC15003, contains at least two of these mechanisms.22, 23 In a unified model for self-
resistance to the BLM family of antibiotics, BlmA and BlmB provide the primary and 
secondary mechanisms of resistance, respectively.24 BlmA noncovalently binds metal-
bound BLMs and sequesters them, preventing the antibiotics from binding to O2, becoming 
active, and cleaving DNA.6, 13, 19 BlmB acetylates the primary amine of the β-aminoalanine 
moiety of metal-free BLMs preventing the formation of activated BLMs by inhibiting the 
metal-chelated complex from coordinating to and/or reducing molecular oxygen.24–28 The 
biosynthetic gene cluster of TLM from Streptoalloteichus hindustanus E465-94 
ATCC3115829 mirrors that of BLM, encoding homologues of both resistance proteins 
(TlmA and TlmB, respectively). The ZBM producer Streptomyces flavoviridis ATCC21892, 
however, lacks a BlmB homologue in its genome,24, 30 yet ZbmA is sufficient to provide 
resistance to ZBM in the producing strain.24
After the structure of Shble (i.e., TlmA) from the TLM-producing S. hindustanus was 
reported in 1994 (PDB 1BYL),31 BLM-binding proteins have been extensively studied 
resulting in numerous high resolution crystal and NMR solution structures. Apo, BLM-
bound, and Cu(II)-BLM-bound structures of BlmA from S. verticillus (PDB 1QTO, 1JIE, 
and 1JIF, respectively)13, 32 and BlmT from the Tn5 transposon from Klebsiella pneumoniae 
(PDB 1ECS, 1EWJ)33 revealed that (i) the BLM-binding proteins form two cooperative 
BLM-binding pockets by dimer formation,13, 31 (ii) the axial ligand of the metal ion is the 
primary amine of the β-aminoalanine moiety,13 (iii) the preferred conformation of the 
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bithiazole moiety is trans, although both isomers are possible,13, 33 and (iv) and BLM’s 
bithiazole moiety, long C-terminal amine, and propionamide moiety of pyrimidoblamic acid 
are important for binding.13 No structures are reported, however, of the ZBM-binding 
protein, ZbmA, nor a BLM- or TLM-binding protein complexed with a member of the BLM 
family possessing a thiazolinyl-thiazole moiety, namely the PLMs or ZBM.
Here, we report the crystal structure of ZbmA, the ZBM-binding protein and primary self-
resistance element in S. flavoviridis ATCC21892, in both its apo and Cu(II)-ZBM bound 
forms at 1.90 Å and 1.65 Å, respectively. Our findings unveiled that (i) the overall structure 
of ZbmA is highly homologous to other BLM-binding proteins, (ii) ZbmA undergoes minor 
conformational changes upon binding ZBM, and (iii) the binding sites of ZbmA have been 
fine-tuned to accept the structurally unique ZBM.
MATERIALS AND METHODS
Gene cloning and expression and protein overproduction and purification
Sesame was used as the laboratory information system for project information and reporting 
to the PSI Target Track Database.34 The full length zbmA gene from S. flavoviridis 
ATCC21892 (NCBI accession, gi: 195970725; locus version: ACG60763) was amplified by 
PCR from genomic DNA with KOD Hot Start DNA polymerase, amplification buffer 
supplemented with betaine to a final concentration of 2.5 M, and the following forward and 
reverse primers, 5′-TACTTCCAATCCAATGCCATGGCCGTATTGCTCTCGGGG-3′ and 
5′-TTATCCACTTCCAATGTTAACGAACCGTCCGGGTCGTTTC-3′, respectively. The 
PCR product was purified, treated with T4 polymerase,35 cloned into pMCSG57 according 
to ligation-independent procedures,36, 37 and transformed into E. coli BL21(DE3)-Gold 
(Stratagene). Protein production, purification, and His6-tag cleavage were carried out as 
described previously38 and resulted in protein with a Ser-Asn-Ala peptide preceding the N-
terminal Met. During the first batch of protein production, used for the crystallization of apo 
ZbmA, methionine biosynthetic inhibitory amino acids (25 mg L−1 each of L-valine, L-
isoleucine, L-leucine, L-lysine, L-threonine, L-phenylalanine) and L-selenomethionine 
(SeMet, Medicillin) were added before isopropyl β-D-1-thiogalactopyranoside (IPTG) 
induction. A second batch of protein was purified for optimization with reductive alkylation 
and partial proteolysis.39 For cocrystallization of ZbmA with Cu(II)-ZBM, the inhibitory 
amino acids and SeMet were not added during protein production. Protein concentrations 
were determined from the absorbance at 280 nm using a calculated molar absorptivity 
constant (ε280 = 23,490 M−1 cm−1).40 The concentration of pure protein samples used for 
crystallization was 58.5 mg mL−1 for unmodified ZbmA, 49.6 mg mL−1 for reductively 
methylated, 51.0 mg mL−1 for reductively ethylated, 46.6 mg mL−1 for reductively 
isopropylated, 51.4 mg mL−1 for partial proteolysis (with chymotrypsin, trypsin, or 
thermolysin), and 41.0 mg mL−1 for unmodified ZbmA cocrystallization with Cu(II)-ZBM. 
Individual aliquots of purified protein were stored at −80 °C until use.
Protein crystallization
ZbmA was screened against several commercially available crystallization conditions 
including MCSG-1–3 (Microlytic) at 24 °C and 4 °C for the unmodified protein, MCSG-1–4 
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at 16 °C for the reductively alkylated proteins and protein-ligand complex, and PEG/Ion HT 
(Hampton Research Corp.) at 16 °C for the partially proteolyzed proteins. The protein-
ligand complex was prepared by mixing ZbmA with 10 mM Cu(II)-ZBM at 4 °C for several 
hours before crystallization. Cu(II)-ZBM was isolated from S. flavoviridis SB9001 as 
previously reported.17 Vapor-diffusion sitting drops containing 0.4 μ;L of protein and 0.4 
μ;L of screening solution were set up in 96-well CrystalQuick plates (Greiner Bio-one) over 
wells containing 140 μ;L of screening solution using a Mosquito liquid dispenser (TTP 
Labtech). While crystals were obtained under several conditions, the best apo ZbmA crystal 
was obtained from the reductively isopropylated ZbmA at 16 °C with a reservoir solution 
containing 0.8 M ammonium sulfate and 0.1 M sodium citrate, pH 4.0. The best Cu(II)-
ZBM-bound ZbmA crystal was obtained at 16 °C with a reservoir solution containing 0.1 M 
phosphate-citrate, pH 4.2, 40% (v/v) glycerol, and 5% (w/v) polyethylene glycol 1000. The 
crystals grew within one month and were cryoprotected and flash frozen in liquid nitrogen.
Data collection, structure determination, and refinement
Diffraction data were collected on the 19-BM and 19-ID beamlines of the Structural Biology 
Center at the Advanced Photon Source.41 Data were collected to 1.90 Å and 1.65 Å at the 
peak wavelengths (0.97929 and 0.97918 Å) for the single best apo ZbmA and Cu(II)-ZBM-
bound ZbmA crystals, respectively. Data were processed using the HLK-3000 program.42 
For SeMet-labeled apo ZbmA, single-wavelength anomalous diffraction (SAD) was used for 
phasing and an initial model was built using the program suite HKL-3000. The model was 
completed manually with Coot.43 For native Cu(II)-ZBM-bound ZbmA, the structures were 
determined by molecular replacement using apo ZbmA as the starting model. All final 
models were refined with Refmac544 from the CCP4 suite45 or PHENIX.46 The models 
were analyzed and validated using MolProbity47 and Coot validation tools.43 The final 
atomic coordinates and amplitudes were deposited in the Brookhaven Protein Data Bank, 
entry codes 4IAG and 5CJ3 for the apo and Cu(II)-ZBM-bound forms of ZbmA, 
respectively. Figures were prepared using PYMOL (Schrödinger, LLC) and structures were 
visually examined using a collaborative stereographic system.48
RESULTS AND DISCUSSION
Bioinformatics analysis of ZbmA revealing key differences in ligand binding site
An amino acid sequence alignment containing members of the BLM-binding protein family 
(Fig. 2) showed ZbmA shares high sequence homology with both BlmA (50% identity and 
74% similarity) and TlmA (Shble, 56% identity and 74% similarity), yet low homology with 
the transposon Tn5 homologue BlmT (21% identity and 50% similarity). Given the 
structural nature of the BLM family of natural products, including the strictly conserved 
metal-binding domain, many of the residues in ZbmA proposed to bind ZBM are also 
conserved throughout the BLM-binding family. However, differences in the linker and 
DNA-binding domains of ZBM likely brought about evolutionary changes to its 
corresponding resistance protein resulting in a binding protein optimized for ZBM 
sequestration. Three key residues in ZbmA represent this likely evolutionary optimization: 
Thr35, Glu47, and Arg98. Sequence alignments and structures of BlmA, TlmA, and BlmT 
suggest that both Thr35 and Glu47 are in close proximity to the DNA-binding domain of 
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ZBM, a region with two major differences (i.e., its thiazolinyl-thiazole moiety and unique 
terminal amine) between ZBM and the other members of the BLM family. The Arg98 
counterpart in BlmT, Glu95 (Gly98 in BlmA and TlmA), helps form an outside wall near the 
linker domain of BLM, foreshadowing a potential interaction of Arg98 in ZbmA with the 
linker domain of ZBM. Another conspicuous active site residue difference in ZbmA is 
Gln63 (Ser or Leu in other members). In an attempt to construct a selectable marker for 
hyperthermophiles, the Shble resistance protein was randomly mutated.49 Interestingly, the 
Leu63Gln mutation had a central role in thermostability as it was found in three of the five 
thermostable mutants. Structural analysis showed that Gln63Shble was involved in an 
extensive H-bond network. While BlmA and BlmT possess Ser63, which may contribute to 
a similar H-bond network, ZbmA appears to already have the preferred Gln63.
Crystallization, data collection, and structural refinement
Apo ZbmA crystallized in many conditions; however, the best crystals were obtained from 
reductively isopropylated ZbmA. It is not clear from the structure why reductive 
isopropylation lead to the best crystals. However, the single lysine residue is accessible on 
the surface of the protein and is in close proximity to another isopropyl lysine of a symmetry 
mate, resulting in crystal contacts. Apo ZbmA crystallized in the space group P6522 with 
cell dimensions of a = b = 38.79 Å × c = 268.52 Å and one molecule per asymmetric unit. 
The structure was solved by Se-SAD with phasing from a single selenomethionine. Data 
collection and refinement statistics can be found in Table 1. The final refinement statistics 
are reasonable with an Rwork of 0.183, Rfree of 0.231, and resolution of 1.90 Å. Electron 
density revealed the presence of residues Ala2–Ser122 with residues Ser-2–Met1 and 
Glu123–Arg132 missing. One molecule of glycerol, eight molecules of 1,2-ethanediol, and 
55 water molecules were also visible in the electron density.
The best crystals of Cu(II)-ZBM-bound ZbmA were obtained by using the unmodified 
ZbmA. Complexed ZbmA crystallized in the space group P212121 with cell dimensions of a 
= 40.74 Å × b = 78.99 Å × c = 79.54 Å and two molecules per asymmetric unit. The 
structure was solved by molecular replacement using apo ZbmA as the starting model. Data 
collection and refinement statistics can be found in Table 1. The final refinement statistics 
are reasonable with an Rwork of 0.176, Rfree of 0.231, and resolution of 1.65 Å. Electron 
density revealed the presence of residues Ser-2A–Glu123A and Met1B–Glu126B with 
residues Ala124A–Arg132A, Ser-2B–Ala0B, and Thr126B–Arg132B missing. Two molecules 
of Cu(II)-ZBM and 165 water molecules were also visible in the electron density. As 
previously described for Cu(II)-BLM,13 the Cu(II) ion is chelated by the five metal-binding 
nitrogens of ZBM and a chloride ion forming a tetragonal bipyramidal coordination complex 
(Figs. 1 and 3). The electron density for part of the linker domain and thiazolinyl moiety of 
ZBM shows some discontinuity, whereas the density for the metal-binding domain, 
disaccharide moiety, 3-aminopropionamidine C-terminal amine, and the thiazole moiety are 
apparent and clear (Fig. 3). The presence of additional electron density near the terminal 
amine suggested a secondary conformation for the thiazolinyl-thiazole and 3-
aminopropionamidine moieties, modeled in an occupancy of 45%.
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The overall structure of ZbmA revealing structural similarity to known BLM-binding 
proteins
As expected given the conserved nature of the family of BLM-binding proteins, the overall 
secondary (Fig. 2) and tertiary structure (Fig. 4A) of ZbmA showed high similarity to that of 
the structurally characterized homologues.31–33 Superposition of the backbone atoms of 
Cu(II)-ZBM-bound ZbmA on those of BlmA (PDB 1JIF), TlmA (Shble, PDB 1BYL; 
thermostable mutant, PDB 1XRK), and BlmT (PDB 1EWJ) gave root-mean-square 
deviations (RMSD) of 0.523 Å, 0.333 Å, 0.359 Å, and 2.096 Å, respectively, supporting the 
structural conservation found among all members of the BLM-binding protein family. The 
topologies of both the monomeric apo ZbmA and the dimeric Cu(II)-ZBM-bound ZbmA are 
identical with each monomer containing N- and C-terminal domains with β-α-β-β-β 
topologies. The N-terminal domain, comprised of the α1-helix and a four stranded β-sheet 
(β1–β4), and the C-terminal domain, comprised of the α2-helix and a five-stranded β-sheet 
(β5–β9), are joined by a short 310-helix (η1). The N-terminal β1-strand contributes to dimer 
formation and stabilization by alternate arm exchange between two ZbmA monomers, as 
previously described for other BLM- and TLM-binding proteins.31–33
ZbmA undergoes minor conformational changes when binding Cu(II)-ZBM
Cu(II)-ZBM-ZbmA forms a dimer with two binding pockets, each consisting of a large 
concavity and an interfacial groove housing one Cu(II)-ZBM molecule. With the exception 
of a noncrystallographic 2-fold axis displaying a dimer containing the aforementioned β1-
strand alternate arm exchange, the overall structure of ZbmA complexed with Cu(II)-ZBM 
is nearly identical to apo ZbmA (Fig. 4B). Superposition of the backbone atoms of apo 
ZbmA with both chains of complexed ZbmA revealed no major conformational changes 
upon Cu(II)-ZBM binding (RMSDs of chain A and B were 0.147 Å and 0.226 Å, 
respectively). A major conformational change was seen in BlmA after binding to BLM 
A2.13 The β-turn from Ser100 to Gly103 underwent a dramatic loop shift of 5.4 Å and 3.6 Å 
for the Pro101 in chain A and B, respectively, upon BLM A2 binding. This shift was 
attributed to Pro101 forming a hydrophobic interaction with the bithiazole moiety in BLM 
A2 and brought about increased structural rigidity in the β-turn. Upon ZBM binding to 
ZbmA, the analogous β-turn from Val100 to Gly103 in ZbmA only shifted Pro101 by 0.9 Å. 
The presence of Trp102 in ZbmA (Ala102 in BlmA) may explain this delicate loop shift. 
Trp102, in both the apo and complexed forms, lies directly across from Phe38 of the other 
chain and forms one side of the interfacial groove that binds the thiazolinyl-thiazole moiety 
(Fig. 4C). The inherent presence of this hydrophobic residue minimizes the need for ZbmA 
to alter its conformation as Trp102 is already in prime position to interact with the antibiotic. 
Interestingly, TlmA and BlmT also possess a Trp residue in that position and exhibit similar, 
relatively minor conformational changes of 2.6 Å and 1.9 Å, respectively.
Inspection of the side chains of ZbmA in the apo and Cu(II)-ZBM bound forms revealed two 
residues that undergo noteworthy changes upon antibiotic sequestration. The phenyl ring of 
Phe38, one of the residues forming the thiazolinyl-thiazole-binding groove, rotates ~80° 
upon binding ZBM (Fig. 4C). This rotation not only widens the groove but sets up sandwich 
π-stacking interactions with the thiazole moiety of ZBM. In the concavity pocket of the 
ligand binding site, the long flexible side chain of Arg98 adopts a different rotamer upon 
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binding to ZBM (Fig. 4C), positioning the guanidinium group near three separate oxygens in 
the linker domain (see below for detailed description). As none of the other BLM-binding 
proteins possess an Arg at this position (Gly or Glu), yet each antibiotic has the same three 
oxygens in the linker domain, Arg98 in ZbmA affords three additional hydrogen bonds, 
hence additional sites for interacting with the ZBM antibiotic.
Cu(II)-ZBM-ZbmA structure revealing key binding interactions
As seen in previous BLM-binding proteins, the dimer interface of ZbmA, burying almost 
4000 Å2 of solvent accessible surface area, creates two antibiotic-binding pockets each 
consisting of a concavity and an aromatic groove (Fig. 5A).31–33 The metal-binding domain 
and disaccharide moiety reside in the concavity. The linker domain, also in the concavity, 
loses reliable electron density towards the thiazolinyl moiety supporting the flexible and 
disordered nature of this region (Fig. 3). The C-terminal 3-aminopropionamidine and 
thiazole moiety showed excellent electron density and was modeled accordingly (mode 1). It 
was clear, however, from additional unmodeled density that a second conformation was also 
possible (mode 2). Therefore, both conformations were modeled into each binding site (Fig. 
3). While these moieites lie in the aromatic groove in both modes, mode 1 sits deeper in the 
groove making a number of stabilizing interactions with ZbmA and is likely the preferred 
binding mode. Over half (~780 Å2) of the total surface area of ZBM (~1530 Å2) is buried 
through interactions with ZbmA.
As both monomers of ZbmA and both bound molecules of Cu(II)-ZBM show minimal 
differences, the following descriptions are based on the Cu(II)-ZBM molecule in chain A. 
The metal-binding domain and sugars of ZBM form an extensive hydrogen bonding network 
with residues lining the binding pocket and coordinated water molecules (Fig. 5B). These 
interactions make up the majority of the interactions necessary for ZbmA to sequester the 
antibiotic. The phenolic oxygen of Tyr86A and the side chain of Arg109A interacts with the 
4′-hydroxyl of mannose. The side chain of Tyr86A also hydrogen bonds with the 
carboxamide oxygen of the pyrimidine ring. The 6′-hydroxyl of mannose coordinates with 
the carbonyl oxygen of β-hydroxyhistidine through a single hydrogen bonded water 
molecule. The 3′-O-carbamoylmannose moiety appears to be a key proponent in the 
hydrogen bonding network. Although it is involved in a complicated hydrogen bonding 
network, Asp60A is the only residue that directly interacts with it; one of the side chain 
oxygens of Asp60A hydrogen bonds with the nitrogen of the carbamoyl group. The other 
side chain oxygen of Asp60A, the backbone carbonyl oxygen of Ala89A, and the side chain 
nitrogen of Gln56A, all coordinate waters in the hydrogen bonding network. The carbonyl 
oxygen of the carbamoyl moiety also appears to form a key hydrogen bonding network with 
the backbone oxygen of Asp60A, the 3′-hydroxyl of 6-deoxy- L-gulose, and the primary 
amine of β-aminoalanine. The three backbone carbonyl oxygens of Pro59A, Thr62A, and 
Gly113A form hydrogen bonds with the amino group of the pyrimidine ring and both the 
side chain hydroxyl and backbone oxygen of Ser52B coordinate a water molecule that 
hydrogen bonds with the nitrogen of the propionamide moiety. The side chain of Gln63A, 
the key residue in the thermostable Shble mutant, is in close proximity to the propionamide 
amide nitrogen, but instead, along with the backbone oxygen of Asn61A, forms a hydrogen 
bond to a water molecule.
Rudolf et al. Page 7
Biochemistry. Author manuscript; available in PMC 2016 November 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The linker domain shows a limited number of stabilizing interactions, reflecting its 
disordered nature (Fig. 5C). Arg98A, the residue that rotates upon binding to Cu(II)-ZBM, is 
the only direct protein-ligand interaction with the linker domain and forms three hydrogen 
bonds with the 3′-hydroxyl of methylcaproate, and the side chain and backbone carbonyl 
oxygens of hydroxyvaline. Gln63A, Thr95A, Glu105A, and His117A all line the cavity near 
the linker domain, but do not appear to make any direct interactions. The 6′-hydroxyl of 
methylcaproate twists towards the carbonyl oxygen of β-hydroxyhistidine forming an 
intramolecular hydrogen bond.
The C-terminal thiazolinyl-thiazole and 3-aminopropionamidine moieties reside in a groove 
created by the dimer interface (Fig. 5C). Trp65A, Trp102A, Phe33B, Phe38B, and Phe49B 
form the hydrophobic faces of the groove that holds the thiazolinyl-thiazole moiety. The 
side chain nitrogens of Arg67A hydrogen bond with the carbonyl oxygen of the thiazole 
ring. Glu32B and Leu121A help form a pocket where the C-terminal amine lies, but the side 
chain of Glu47B makes the vital interaction with a nitrogen on the amidine functional group.
Comparisons between the ZBM-, TLM-, and BLM-binding proteins revealing ZbmA is fine-
tuned to sequester ZBM
An overlay of ZBM (from 5CJ3) and BLM A2 (from 1JIF)13 reveals little variation between 
their metal-binding domains and sugar moieties with the main difference a minor 
displacement of the β-hydroxyhistidine and disaccharide moieties. This results in the 
carbamoyl moiety of the mannose in ZBM forming a hydrogen bond network to bind with 
the primary amine of β-aminoalanine instead of an intramolecular hydrogen bond as seen in 
BlmA (Fig. 5B). The linker domain of BLM mainly interacts with BlmA through water 
molecules; also a plausible scenario in ZbmA. However, one significant difference is that 
the flexible Arg98A in ZbmA extends out from the cavity wall to interact with three separate 
oxygens. Having no side chain, Gly98 in BlmA and TlmA is unable to make these contacts 
(Fig. 4C). Given the flexibility of the linker domains and C-terminal amines of ZBM and 
BLM, and consequently incomplete electron densities, it is understandable the biggest 
variation is in those regions. The one constant feature is that the thiazole in ZBM is 
positioned in an identical location as the C-terminal thiazole in BLM (Fig. 5D). The 
nonaromatic thiazolinyl moiety of ZBM sits on the edge of the highly hydrophobic groove, 
placing the aromatic thiazole between the five aromatic residues, including Trp102A, that 
form the hydrophobic groove. The excellent electron density of the preferred binding mode 
for the C-terminal amine of ZBM (Fig. 3E) provides an opportunity to reassess the modeled 
γ-aminopropyldimethylsulfonium moiety of BLM A2.13 The crystal structures of BlmA and 
the thermostable Shble mutant with BLM A2 both lacked electron density for the C-terminal 
amines.13, 49 Similarly to ZBM, the C-terminal amine of BLM A2 was modeled into two 
modes based on the electron density of the bithiazole moiety (Fig. 5D). The tail of one of the 
conformations was proposed to wrap around placing the sulfonium moiety near the 3-
aminopropionamidine of ZBM. In BlmA, electrostatic repulsion shifts the positively charged 
side chain of Arg47B away from the sulfonium moiety upon BLM A2 binding.13 In ZbmA, 
the negatively charged Glu47B requires no conformational shift upon ZBM binding.
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CONCLUSION
The BLM family of natural products are structurally complex. One member of this family, 
ZBM, differs structurally from other members in its disaccharide moiety and linker and 
DNA-binding domains. Although it is unclear which member of the BLM family is 
ancestral, evolutionary divergence in the biosynthesis and structure of ZBM likely brought 
about concomitant evolutionary changes to its corresponding resistance mechanisms.14, 24 
These changes resulted in a binding protein optimized for ZBM sequestration. This study 
describes the high-resolution crystal structure of the ZBM-binding protein ZbmA, both in its 
apo and Cu(II)-ZBM-bound forms. Comparison and contrast with other structurally 
characterized members of the BLM-binding protein family revealed key differences in the 
protein-ligand binding environment that fine-tunes the ability of ZbmA to sequester Cu(II)-
ZBM.
Members of the BLM family are activated by binding a metal(II) ion and molecular oxygen 
(O2) that undergoes reduction to form a BLM-metal(III)-OOH complex.3 With two 
complementary resistance mechanisms, an N-acetyltransferase that disrupts the essential 
metal-binding domain by modifying the metal-free drug and a binding protein that 
sequesters the metal-bound drug, the BLM and TLM producing strains are extremely well-
equipped to prevent activation of their lethal natural products.24 In an intriguing example of 
secondary metabolism and self-resistance evolution, the ZBM producer, S. flavoviridis 
ATCC21892, possesses the binding protein but lacks the N-acetyltransferase 
homologue.24, 30 Therefore, S. flavoviridis foregoes a secondary resistance mechanism and 
solely relies on the ZbmA binding protein for resistance against ZBM. These insights, the 
crystal structure of ZbmA, and the fact that Cu(II)-ZBM complexes are isolated, support 
drug sequestration of metal-bound ZBM as the primary resistance mechanism in S. 
flavoviridis, a model that extends to all producing organisms of the BLM-family of 
antitumor antibiotics.24
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Figure 1. 
Structures of selected members of the BLM family of antitumor antibiotics. The five 
nitrogen atoms that coordinate the metal ion are bolded in red and structural differences 
between the antibiotics are highlighted with dotted blue boxes. The four structural domains 
of BLMs and the structural components of ZBM are labeled.
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Figure 2. 
Sequence alignment of selected BLM-binding proteins that have been structurally 
characterized. Aligned residues are colored based on level of conservativity (red box with 
white character is strict identity, red character is similarity, blue frame is similarity across 
groups). Corresponding secondary structures are depicted above the sequence alignment 
with gray stars representing residues with multiple conformations. The accessible surface 
area (acc; white are buried residues, cyan are intermediate, blue are accessible), hydropathy 
(hyd; pink are hydrophobic residues, gray are intermediate, cyan are hydrophilic), and 
protein-ligand contacts of Cu(II)-ZBM-bound ZbmA (A, B, and * with yellow backgrounds 
are non-crystallographic contacts with chain A, chain B, or ZBM, respectively; A, B, and * 
are crystallographic contacts; orange background signifies both non- and crystallographic 
contacts, red is < 3.2 Å, black is 3.2 – 5.0 Å, blue frame signifies both protein-protein and 
protein-ligand contacts) from 5CJ3 are depicted below the sequence alignment. The 
alignment was created with MUSCLE50 and rendered with ESPript 3.051 and ENDscript 
2.0.52
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Figure 3. 
Electron density map for Cu(II)-BLM. The 2mFo – DFc omit map for the ZbmA-Cu(II)-
ZBM complex in chain A with a 1.0σ contour (gray). Copper and chloride atoms are shown 
in teal and purple, respectively. (A) Overall structure of Cu(II)-ZBM. (B) Metal-binding 
domain comprised of β-aminoalanine, pyrimidylpropionamide, and β-hydroxyhistidine. (C) 
Unique disaccharide of 6-deoxy- L-gulose-3-O-carbamoyl- D-mannose. (D) Linker domain 
containing methylcaproate and hydroxyvaline. (E) Two binding modes for the DNA-binding 
domain comprised of the thiazolinyl-thiazole and 3-aminopropionamidine moieties.
Rudolf et al. Page 15
Biochemistry. Author manuscript; available in PMC 2016 November 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
Overall structure of ZbmA and comparison of the apo and Cu(II)-ZBM-bound structures. 
(A) Superposition of ZbmA (green, 5CJ3) with BlmA (magenta, 1JIF), TlmA (orange, 
1BYL), and BlmT (blue, 1EWJ). (B) Superposition of apo ZbmA monomer (yellow, 4IAG) 
with the Cu(II)-ZBM-bound ZbmA dimer (chain A green, chain B cyan, 5CJ3). The 
secondary structure features are labeled as depicted in Fig. 2. The ZBM molecules are 
shown as sticks with copper and chloride atoms shown as teal and purple spheres, 
respectively. (C) Differences between the apo and Cu(II)-ZBM-bound ZbmA structures. The 
coloring scheme is the same as in (B), with the addition of apo BlmA (gray, 1QTO) and 
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Cu(II)-BLM A2-bound BlmA (magenta, 1JIF) shown for comparison. The side chains of 
both F38 and R98 rotate upon binding Cu(II)-ZBM to form interactions with the antibiotic. 
In contrast to BlmA, the loop including P101 and W102 in ZbmA undergoes only a minor 
shift due to the inherent presence of W102 (A102 in BlmA) along the thiazole-binding 
groove. The second binding mode of the linker and DNA-binding domains for ZBM was 
removed for clarity. The surface of the ZbmA dimer is shown in the background.
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Figure 5. 
Binding modes of Cu(II)-ZBM with ZbmA. (A) Overall view of the binding modes of 
Cu(II)-ZBM in the dimer interface of ZbmA. ZBM (white sticks) with copper and chloride 
atoms shown as teal and purple spheres, respectively, depicted with the surface of chains A 
(green) and B (cyan). The metal-binding and linker domains, along with the disaccharide 
moiety resides in the large concavity. The DNA-binding domain resides in the interfacial 
groove. (B) Hydrogen-bonding network between ZbmA and the metal-binding domain and 
disaccharide moiety of Cu(II)-ZBM. Hydrogen bonds are shown as dotted, black lines. (C) 
Hydrogen-bonding, π-stacking, and hydrophobic interactions between ZbmA and the linker 
and DNA-binding domains of ZBM. R98A and E47B, unique to ZbmA, make key hydrogen 
bonds with ZBM. W102A is perfectly positioned for sandwich stacking with the thiazole of 
ZBM. (D) The two binding modes of Cu(II)-ZBM in ZbmA overlayed with the two binding 
modes of Cu(II)-BLM A2 (1JIF). The thiazole of ZBM (mode 1) and the penultimate 
thiazole of BLM A2 overlap with each other and reside deep within the aromatic groove. 
The thiazolinyl-thiazole and 3-aminopropionamidine moieties of ZBM (mode 1) lay 
completely within the groove; only the thiazole moiety of ZBM (mode 2) resides in the 
groove.
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Table 1
Data Collection and Refinement Statistics
Data set Apo WT-Cu(II)-ZBM
Space group P6522 P212121
Unit cell a = b = 38.79 Å, c = 268.52 Å; α = β = 90°, γ = 120° a = 40.74 Å, b = 78.99 Å, c = 79.54 Å; α = β = γ = 120°
Wavelength (Å) 0.97929 0.97918
Resolution range (Å)a 32.59 – 1.90 (1.93 – 1.90) 35.52 – 1.65 (1.66 – 1.65)
Unique reflections 10484 (460) 29473 (603)
Multiplicity 9.7 (4.0) 7.9 (5.6)
Completeness (%) 98.5 (87.5) 93.0 (79.8)
I/σI 33.0 (2.2) 34.7 (5.3)
Wilson B-factor 28.2 12.66
Rmerge (%)b 6.8 (43.4) 5.7 (37.4)
Rmeas (%)c 7.3 6.1
CC1/2 0.795 0.931
CC*d 0.941 0.982
Phasing and refinement
 Resolution (Å) 32.59 – 1.90 (1.95 – 1.90) 35.52 – 1.65 (1.67 – 1.65)
 Number of reflections 10242 (639) 29164 (1989)
 Rwork/Rfree (%) 18.3/23.1 (28.5/36.8) 17.6/21.3 (19.5/27.1)
Number of atoms 946 2575
Residues
 Macromolecules 121 270
 Ligand/ion 9 6
 Water 55 165
RMSD bond (Å) 0.016 0.013
RMSD angle (°) 1.836 1.788
Ramachandran plot (%)e
 Favored 98.4 98.9
 Outliers 0.0 0.0
 Clashscore 10.1 2.52
Ligands RSCCf - 0.84
Average B-factor 38.3 17.5
 Macromolecules 37.0 16.0
 Ligands 49.2 21.7
 Water 48.0 26.1
PDB ID 4IAG 5CJ3
aNumbers in parentheses are values for the highest-resolution bin
b
Rmerge = ΣhklΣi|Ii(hkl) − (hkl)|/ΣhklΣiIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, and Ī(hkl) is the weighted average intensity 
for all observations i of reflection hkl
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c
Rmeas = Σhkl (N/(N − 1)1/2)Σi |Ii (hkl) − Ī (hkl)|/Σhkl Σi Ii (hkl)
dCC* = (2CC1/2/(1 + CC1/2))1/2
eAs defined by MolProbity
f
Ligand RSCC: ZBM real-space correlation coefficient
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